6-K - Galapagos N.V. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Galapagos NV released its 2025 annual report and announced April 28, 2026 shareholders meetings with material voting proposals for investors.

Key Takeaways

12025 full-year net profit of EUR 316.9 million, up from EUR 47.8 million in 2024.

2Proposed company name change to Lakefront Biotherapeutics, effective May 8, 2026 if approved.

3Gino Santini nominated as independent director, intended to serve as Board Chair post-approval.

4Proposal to authorize share buybacks of up to 10% of outstanding shares for 5 years.

5Proposal to renew board authorization for up to 20% share capital increases for 5 years.

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Results of Operations

Full Year 2025

Metric	Value	Prior Period
Revenue	$1.10B	$303.4M
Operating Profit	$390.2M	$-207.7M
Net Income	$316.9M	$47.8M

Executive & Director Changes

Henry Gosebruch

Executive Director

Appointment (confirmation of co-optation)

Effective: 2025-05-12

Fill vacancy following resignation of Paul Stoffels

Gino Santini

Independent Non-Executive Director

Appointment (pending shareholder approval)

Effective: 2026-04-28

Succeed Jérôme Contamine as Board Chair

Exhibits (14)

6-K

99.1

EX-99.1

99.10

EX-99.10

99.11

EX-99.11

99.12

EX-99.12

99.13

EX-99.13

99.2

EX-99.2

99.3

EX-99.3

99.4

EX-99.4

99.5

EX-99.5

99.6

EX-99.6

99.7

EX-99.7

99.8

EX-99.8

99.9

EX-99.9